Crystal ball time: Looking ahead at T-DM1, Invokana, BG-12
This article was originally published in Scrip
When it comes to the US FDA, nothing is ever guaranteed – as Novo Nordisk learned the hard way over the weekend after getting slapped with an icy-cold mid-winter complete response letter (CRL) for its investigational Type I and Type II diabetes treatments Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.